drugset / Trial / NCT02666209
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
Summary
Participant that has been diagnosed with Relapsed/ Refractory Multiple Myeloma and are currently participating in a clinical trial which is closing. This research study is studying Ulocuplumab as a possible treatment. It's an expanded access from NCT01359657
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ulocuplumab | Monoclonal antibody | — | Intravenous |
| Background | Bortezomib | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Lenalidomide | Other / unclassified | — | Oral |